N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 3 N=22 Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
Phase 3 N=36 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 3 N=109 Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
Heart Diseases · Heart Transplantation
Primary: The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies — 0.70; 0.90; 0.87; 0.79 Densitometry / Densitometry of…
N/A N=194 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Survival — 112; 6; 18; 19 participants
N/A N=29 Thymus Transplantation Safety-Efficacy
Complete DiGeorge Anomaly · DiGeorge Syndrome · DiGeorge Anomaly
Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants
Phase 3 N=193 Psychological Support for Patients With an Implantable Cardioverter Defibrillator
Anxiety · Depression
Primary: Hospital Anxiety and Depression Scale - Depression Scale at Baseline — 4.70; 7.47; 5.35; 4.12 units on a scale
Phase 4 N=434 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Heart Transplantation
Primary: Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant — 77; 104 participants — p=0.007
Phase 2 N=21 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
N/A N=144 Coronary Artery Disease Screening in Kidney Transplant Candidates
End Stage Renal Disease · Coronary Artery Disease
Primary: Number of Participants Adhering to the Expected Number of Screening Tests — 59; 71 participants
Phase 2 N=26 Thymus Transplantation in DiGeorge Syndrome #668
DiGeorge Syndrome · Complete Typical DiGeorge Anomaly
Primary: Survival at 1 Year Post-Cultured Thymus Tissue Implantation (CTTI) — 72 % of participants who survive to 1 year
N/A N=60 Health Coaching to Improve Self-Management in Thoracic Transplant Candidates
Self-management · Lung Transplant · Heart Transplant
Primary: Score on Follow-up Self-Management Ability Scale (SMAS-30) — 75.06; 71.47 score on a scale
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
Phase 4 N=36 Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Number of Subjects With a Perfusion Defect — 5; 6 Participants
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
Phase 4 N=115 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
Renal Function and Chronic Allograft Vasculopathy
Primary: Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation — 79.8; 61.5 mGFR ml/min
Phase 2 N=110 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Phase 2 N=14 Phase I/II Thymus Transplantation With Immunosuppression #950
DiGeorge Anomaly · Complete DiGeorge Anomaly · Complete Atypical DiGeorge Anomaly
Primary: Survival at 1 Year Post-CTTI — 71 % of participants who survive to 1 year
Early Phase 1 N=30 Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours
Phase 2 N=18 Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
Cardiac Allograft Vasculopathy
Primary: Insulin Levels Area Under Curve(AUC) — -47.7; 10.7 h*pmol/L
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
N/A N=30 Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF
Phase 4 N=150 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
Phase 4 N=181 Everolimus in de Novo Heart Transplant Recipients
Cardiac Transplantation
Primary: Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group — 40; 30 participants — p=0.1043
N/A N=24 Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants